FDA Issues Final Guidance on Psychedelic Drug Trials

SILVER SPRING – The FDA published its final guidance titled “Psychedelic Drugs: Considerations for Clinical Investigations” in the Federal Register, finalizing a draft that first appeared in June 2023. Issued by the Center for Drug Evaluation and Research, the document gives sponsors general considerations for developing compounds including psilocybin, LSD, and MDMA as treatments for psychiatric disorders and substance use disorders.

Drug development programs in this category are subject to the same regulations and evidentiary standards as any other investigational product. Where the guidance breaks new ground is in its treatment of a problem structurally embedded in every psychedelic trial: functional unblinding.

Functional unblinding occurs when participants in a supposedly double-blind study can accurately identify whether they received the active drug or a placebo – with psilocybin, LSD, or MDMA, the perceptual effects are unmistakable, and that clarity biases both expectations and reported outcomes. The FDA cited this as a central factor in its 2024 rejection of Lykos Therapeutics’ MDMA-assisted therapy for PTSD, a ruling that led the company to cut roughly three-quarters of its staff within weeks.

The July 2026 guidance codifies the agency’s preferred solutions. Sponsors should consider alternatives to inert placebos like sub-perceptual doses of the investigational compound, administer expectancy evaluation questionnaires before randomization and at the end of treatment, and use a Likert scale assessment to evaluate the impact of functional unblinding. On trial architecture, the guidance proposes pairing a placebo-controlled study with a separate dose-response study using low, middle, and high doses but no placebo at all, letting the no-placebo arm characterize the drug’s dose-response relationship with less unblinding risk, while the placebo arm anchors safety comparisons.

The guidance also addresses the psychotherapy component directly, stating that “the contribution of the psychotherapy component” to observed efficacy “has not been characterized.” The agency recommends that sponsors measure drug effects and psychological support outcomes as separate variables – a requirement with direct implications for how integrated therapy models will be labeled if approved.

The guidance arrived inside an active federal policy window. Executive Order 14401, signed by President Trump on April 18, 2026, acknowledged that individuals with serious mental illness may not respond to existing therapies and directed agencies to accelerate psychedelic drug research and approval. A week after, the FDA announced Commissioner’s National Priority Vouchers, compressing agency review to one or two months, for three psychedelic-focused companies:

• Compass Pathways,
• the Usona Institute, and
• Transcend Therapeutics.

FDA Commissioner Marty Makary has said publicly he expects at least one approval decision by late 2026.

Compass has already submitted portions of its New Drug Application for COMP360, its psilocybin treatment for treatment-resistant depression, and is targeting full submission in Q4 2026, with a commercial launch anticipated in H1 2027, subject to FDA approval and a separate DEA rescheduling action for psilocybin. The agency also announced a public hearing on psychedelic therapeutic use scheduled for September 14, 2026.

For capital markets participants tracking the psychedelics sector, this guidance resets competitive expectations across the entire development pipeline. Functional unblinding is no longer an interpretive gray zone. It is a named, documented challenge with agency-preferred mitigation strategies on record, and programs that built their trial architecture around it early hold a structural edge. As the field advances toward what could be the first FDA-approved classic psychedelic therapy in U.S. history, the quality of a sponsor’s clinical design, not the promise of its compound, will determine what reaches the pharmacy shelf.